Lindsay M. Kipnis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lindsay M. Kipnis has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alison Schwartz Levine
Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA
9 shared publications - Arezou A. Ghazani
Division of Genetics, Brigham and Women’s Hospital, Boston, MA 02115, USA
9 shared publications - Connor P. Hayes
Division of Genetics, Brigham and Women’s Hospital, Boston, MA 02115, USA
9 shared publications - Diane R. Koeller
Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts
9 shared publications - Huma Q. Rana
Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA
9 shared publications - Hyeji Jun
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
9 shared publications
Latest Publications
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Table S1. List of FH variants detected in the 49 patients with atypical uterine leiomyomata with germline genetic testing from the cohort
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Table S1. List of FH variants detected in the 49 patients with atypical uterine leiomyomata with germline genetic testing from the cohort
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Materials and Methods
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Materials and Methods
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Materials and Methods
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Materials and Methods
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Table S1. List of FH variants detected in the 49 patients with atypical uterine leiomyomata with germline genetic testing from the cohort
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Table S1. List of FH variants detected in the 49 patients with atypical uterine leiomyomata with germline genetic testing from the cohort
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Materials and Methods
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Materials and Methods
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Materials and Methods
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Supplementary Materials and Methods
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Data from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Women with germline pathogenic variants (PV) in the fumarate hydratase (FH) gene develop cutaneous and uterine leiomyomata and have an increased risk of developing aggressive renal cell carcinomas. Many of these women are unaware of their cancer predisposition until an atypical uterine leiomyoma is diagnosed during a myomectomy or hysterectomy, making a streamlined genetic counseling process after a pathology-based atypical uterine leiomyoma diagnosis critical. However, the prevalence of germline pathogenic/likely PVs in FH among atypical uterine leiomyomata cases is unknown. To better understand FH germline PV prevalence and current patterns of genetic counseling and germline genetic testing, we undertook a retrospective review of atypical uterine leiomyomata cases at a single large center. We compared clinical characteristics between the FH PV, FH wild-type (WT), and unknown genetic testing cohorts. Of the 144 cases with atypical uterine leiomyomata with evaluable clinical data, only 49 (34%) had documented genetic test results, and 12 (8.3%) had a germline FH PV. There were 48 IHC-defined FH-deficient cases, of which 41 (85%) had FH testing and nine had a germline FH PV, representing 22% of the tested cohort and 18.8% of the FH-deficient cohort. Germline FH PVs were present in 8.3% of evaluable patients, representing 24.5% of the cohort that completed genetic testing. These data highlight the disconnect between pathology and genetic counseling, and help to refine risk estimates that can be used when counseling patients with atypical uterine leiomyomata.Prevention Relevance:Women diagnosed with fumarate hydratase (FH)-deficient uterine leiomyomata are at increased risk of renal cancer. This work suggests a more standardized pathology-genetic counseling referral pathway for these patients, and that research on underlying causes of FH-deficient uterine leiomyomata in the absence of germline FH pathogenic/likely pathogenic variants is needed.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Women with germline pathogenic variants (PV) in the fumarate hydratase (FH) gene develop cutaneous and uterine leiomyomata and have an increased risk of developing aggressive renal cell carcinomas. Many of these women are unaware of their cancer predisposition until an atypical uterine leiomyoma is diagnosed during a myomectomy or hysterectomy, making a streamlined genetic counseling process after a pathology-based atypical uterine leiomyoma diagnosis critical. However, the prevalence of germline pathogenic/likely PVs in FH among atypical uterine leiomyomata cases is unknown. To better understand FH germline PV prevalence and current patterns of genetic counseling and germline genetic testing, we undertook a retrospective review of atypical uterine leiomyomata cases at a single large center. We compared clinical characteristics between the FH PV, FH wild-type (WT), and unknown genetic testing cohorts. Of the 144 cases with atypical uterine leiomyomata with evaluable clinical data, only 49 (34%) had documented genetic test results, and 12 (8.3%) had a germline FH PV. There were 48 IHC-defined FH-deficient cases, of which 41 (85%) had FH testing and nine had a germline FH PV, representing 22% of the tested cohort and 18.8% of the FH-deficient cohort. Germline FH PVs were present in 8.3% of evaluable patients, representing 24.5% of the cohort that completed genetic testing. These data highlight the disconnect between pathology and genetic counseling, and help to refine risk estimates that can be used when counseling patients with atypical uterine leiomyomata.Prevention Relevance:Women diagnosed with fumarate hydratase (FH)-deficient uterine leiomyomata are at increased risk of renal cancer. This work suggests a more standardized pathology-genetic counseling referral pathway for these patients, and that research on underlying causes of FH-deficient uterine leiomyomata in the absence of germline FH pathogenic/likely pathogenic variants is needed.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Data from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Women with germline pathogenic variants (PV) in the fumarate hydratase (FH) gene develop cutaneous and uterine leiomyomata and have an increased risk of developing aggressive renal cell carcinomas. Many of these women are unaware of their cancer predisposition until an atypical uterine leiomyoma is diagnosed during a myomectomy or hysterectomy, making a streamlined genetic counseling process after a pathology-based atypical uterine leiomyoma diagnosis critical. However, the prevalence of germline pathogenic/likely PVs in FH among atypical uterine leiomyomata cases is unknown. To better understand FH germline PV prevalence and current patterns of genetic counseling and germline genetic testing, we undertook a retrospective review of atypical uterine leiomyomata cases at a single large center. We compared clinical characteristics between the FH PV, FH wild-type (WT), and unknown genetic testing cohorts. Of the 144 cases with atypical uterine leiomyomata with evaluable clinical data, only 49 (34%) had documented genetic test results, and 12 (8.3%) had a germline FH PV. There were 48 IHC-defined FH-deficient cases, of which 41 (85%) had FH testing and nine had a germline FH PV, representing 22% of the tested cohort and 18.8% of the FH-deficient cohort. Germline FH PVs were present in 8.3% of evaluable patients, representing 24.5% of the cohort that completed genetic testing. These data highlight the disconnect between pathology and genetic counseling, and help to refine risk estimates that can be used when counseling patients with atypical uterine leiomyomata.Prevention Relevance:Women diagnosed with fumarate hydratase (FH)-deficient uterine leiomyomata are at increased risk of renal cancer. This work suggests a more standardized pathology-genetic counseling referral pathway for these patients, and that research on underlying causes of FH-deficient uterine leiomyomata in the absence of germline FH pathogenic/likely pathogenic variants is needed.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Women with germline pathogenic variants (PV) in the fumarate hydratase (FH) gene develop cutaneous and uterine leiomyomata and have an increased risk of developing aggressive renal cell carcinomas. Many of these women are unaware of their cancer predisposition until an atypical uterine leiomyoma is diagnosed during a myomectomy or hysterectomy, making a streamlined genetic counseling process after a pathology-based atypical uterine leiomyoma diagnosis critical. However, the prevalence of germline pathogenic/likely PVs in FH among atypical uterine leiomyomata cases is unknown. To better understand FH germline PV prevalence and current patterns of genetic counseling and germline genetic testing, we undertook a retrospective review of atypical uterine leiomyomata cases at a single large center. We compared clinical characteristics between the FH PV, FH wild-type (WT), and unknown genetic testing cohorts. Of the 144 cases with atypical uterine leiomyomata with evaluable clinical data, only 49 (34%) had documented genetic test results, and 12 (8.3%) had a germline FH PV. There were 48 IHC-defined FH-deficient cases, of which 41 (85%) had FH testing and nine had a germline FH PV, representing 22% of the tested cohort and 18.8% of the FH-deficient cohort. Germline FH PVs were present in 8.3% of evaluable patients, representing 24.5% of the cohort that completed genetic testing. These data highlight the disconnect between pathology and genetic counseling, and help to refine risk estimates that can be used when counseling patients with atypical uterine leiomyomata.Prevention Relevance:Women diagnosed with fumarate hydratase (FH)-deficient uterine leiomyomata are at increased risk of renal cancer. This work suggests a more standardized pathology-genetic counseling referral pathway for these patients, and that research on underlying causes of FH-deficient uterine leiomyomata in the absence of germline FH pathogenic/likely pathogenic variants is needed.
- 22 March 2024
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 17 (5) , 201-208
Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Women with germline pathogenic variants (PV) in the fumarate hydratase (FH) gene develop cutaneous and uterine leiomyomata and have an increased risk of developing aggressive renal cell carcinomas. Many of these women are unaware of their cancer predisposition until an atypical uterine leiomyoma is diagnosed during a myomectomy or hysterectomy, making a streamlined genetic counseling process after a pathology-based atypical uterine leiomyoma diagnosis critical. However, the prevalence of germline pathogenic/likely PVs in FH among atypical uterine leiomyomata cases is unknown. To better understand FH germline PV prevalence and current patterns of genetic counseling and germline genetic testing, we undertook a retrospective review of atypical uterine leiomyomata cases at a single large center. We compared clinical characteristics between the FH PV, FH wild-type (WT), and unknown genetic testing cohorts. Of the 144 cases with atypical uterine leiomyomata with evaluable clinical data, only 49 (34%) had documented genetic test results, and 12 (8.3%) had a germline FH PV. There were 48 IHC-defined FH-deficient cases, of which 41 (85%) had FH testing and nine had a germline FH PV, representing 22% of the tested cohort and 18.8% of the FH-deficient cohort. Germline FH PVs were present in 8.3% of evaluable patients, representing 24.5% of the cohort that completed genetic testing. These data highlight the disconnect between pathology and genetic counseling, and help to refine risk estimates that can be used when counseling patients with atypical uterine leiomyomata. Prevention Relevance: Women diagnosed with fumarate hydratase (FH)-deficient uterine leiomyomata are at increased risk of renal cancer. This work suggests a more standardized pathology-genetic counseling referral pathway for these patients, and that research on underlying causes of FH-deficient uterine leiomyomata in the absence of germline FH pathogenic/likely pathogenic variants is needed.
- 22 March 2024
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 17 (5) , 201-208
Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata
Women with germline pathogenic variants (PV) in the fumarate hydratase (FH) gene develop cutaneous and uterine leiomyomata and have an increased risk of developing aggressive renal cell carcinomas. Many of these women are unaware of their cancer predisposition until an atypical uterine leiomyoma is diagnosed during a myomectomy or hysterectomy, making a streamlined genetic counseling process after a pathology-based atypical uterine leiomyoma diagnosis critical. However, the prevalence of germline pathogenic/likely PVs in FH among atypical uterine leiomyomata cases is unknown. To better understand FH germline PV prevalence and current patterns of genetic counseling and germline genetic testing, we undertook a retrospective review of atypical uterine leiomyomata cases at a single large center. We compared clinical characteristics between the FH PV, FH wild-type (WT), and unknown genetic testing cohorts. Of the 144 cases with atypical uterine leiomyomata with evaluable clinical data, only 49 (34%) had documented genetic test results, and 12 (8.3%) had a germline FH PV. There were 48 IHC-defined FH-deficient cases, of which 41 (85%) had FH testing and nine had a germline FH PV, representing 22% of the tested cohort and 18.8% of the FH-deficient cohort. Germline FH PVs were present in 8.3% of evaluable patients, representing 24.5% of the cohort that completed genetic testing. These data highlight the disconnect between pathology and genetic counseling, and help to refine risk estimates that can be used when counseling patients with atypical uterine leiomyomata. Prevention Relevance: Women diagnosed with fumarate hydratase (FH)-deficient uterine leiomyomata are at increased risk of renal cancer. This work suggests a more standardized pathology-genetic counseling referral pathway for these patients, and that research on underlying causes of FH-deficient uterine leiomyomata in the absence of germline FH pathogenic/likely pathogenic variants is needed.